Early diagnosis of cancer
means a high chance of recovery.
OnkoTest Carci Reagent is an IVD diagnostic medical device for self-testing for the early detection of possible oncological disease..
1699,00 Kč
High accuracy for malignant tumors
Sensitivity 96.7% Specificity 99.4%
Rapid evaluation
The result is available within 5 minutes.
Easy to use
For the test, use fresh morning urine.
Instructions and proper use
Order test
Simply order the test online.
For the test, use morning urine
(midstream urine).
Evaluation
After 3–5 minutes of reaction,
assess the color change of the liquid.
Simple assessment
Result 1–2–3: negative*
4–5–6–7–8: positive**
*Result 1–2–3: Negative – Tyrosine levels in urine are not elevated.
**Result 4–5: Positive – Tyrosine levels in urine are slightly elevated. We recommend consulting a doctor and monitoring your health status.
**Result 6–7–8: Positive – Tyrosine levels in urine are significantly elevated. We strongly recommend visiting a doctor and addressing the test result without delay.
About OncoTest
OncoTest is a leader in preventive oncology diagnostics for the early detection of cancer in individuals aged 18 and older. Our team of scientists and healthcare professionals has developed a breakthrough solution in the form of a simple self-test for the early detection of malignant tumors in the body, offering a highly user-friendly approach.
The core principle of the test is based on an enhanced Millon’s reagent method, which monitors elevated levels of monohydroxyphenol metabolites (tyrosine)—a type of monohydroxy phenolic amino acids and their metabolites—in urine.
Based on the color change of the mixture in the vial after adding 3 ml of morning urine (midstream), a reaction color cascade reveals whether the urine samples contain elevated levels of these metabolites.
The reagents in the vial and the tyrosine levels in urine exhibit a characteristic chromogenic reaction, which can be used for the clinical diagnosis of intracellular metabolic abnormalities (detection of possible changes or disruptions in human cell metabolism).
The test result must be consulted with a physician.
The test is intended for single use only.
The test is intended for individuals over 18 years of age.
CE 1023 SUKL Code 01119521 ISO 13485
EU CERTIFICATION No. 22 0196 CN/NB
The Carci Reagent in vitro diagnostic self-test device complies with the essential requirements defined in Annex I, Sections A and B, and Annex III §6 of Directive 98/79/EC of the European Parliament and Council, applicable to its intended use, as well as Government Regulation No. 56/2015 Coll.
The following standards have been met in manufacturing and distribution:
EN ISO 13485:2016
EN 13532:2002
EN 13612:2002
EN ISO 14971:2012
EN ISO 15223-1:2016
EN ISO 18113-1:2011
EN ISO 18113-4:2011
EN ISO 23640:2015
+ offers the advantages of convenient use
+ easy handling
+ rapid detection
+ low cost
+ very high sensitivity
+ high specificity
TYROSINE (monohydroxyphenol metabolite) – a marker that plays a key role in the detection of malignant tumors. Its presence may indicate a possible malignancy in the following cancers:
– Stomach cancer
– Esophageal cancer
– Colorectal cancer
– Pancreatic cancer
– Rectal cancer
– Liver cancer
– Prostate, bladder, and kidney cancer
– Cervical and breast cancer
| DISEASE | Sensitivity |
| Malignant tumors | 96.70% |
| Pigmentation disorders | 22.10% |
| Diabetes | 21.50% |
| Gastritis | 15.10% |
| Stomach ulcers | 14.10% |
| Tuberculosis | 8.90% |
| Viral hepatitis | 8.80% |
| Benign prostatic hyperplasia | 7.10% |
| Cholecystitis (gallbladder inflammation) | 7.00% |
| Pneumonia | 6.90% |
| Esophagitis | 5.40% |
| Small intestine inflammation | 4.50% |
| Specificity in the healthy population | 99.4% |
Tested by medical professionals in the Czech Republic and China. Approved by a European notified body (ITC Zlín). Extensive research and testing. Tests conducted on over 8,000 individuals.